Trials / Unknown
UnknownNCT06060132
Risk Analysis of Cardiotoxic Medication Use Due to Sodium Arsenite Chloride Injection
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 400 (estimated)
- Sponsor
- Qianfoshan Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To study the current status of cardiotoxicity of arsenious acid by analyzing the literature, monitoring data, and real-world applications, and to discuss risk factors and preventive and control measures.
Detailed description
Through the project study, the risk rate of cardiotoxicity caused by arsenious acid will be verified and evaluated, and a typical case analysis will be conducted to assess the risk and benefit ratio of clinical use of arsenious acid injection and to formulate preventive measures, so as to guide the holder of the marketing authorization to carry out in-depth safety studies and to ensure the public's safe use of the drug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sodium arsenite chloride injection | Patient use of arsenite sodium chloride injection |
Timeline
- Start date
- 2023-01-29
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
- First posted
- 2023-09-29
- Last updated
- 2023-09-29
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06060132. Inclusion in this directory is not an endorsement.